Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Timmerman Report turned on the lights one month ago. Thanks to you and many other subscribers like you, it’s off to a terrific start.
Now it’s time to celebrate.
Please mark your calendars for 4 pm Friday, Mar. 20 at the Agora Conference Center at 1551 Eastlake Avenue East in Seattle. This will be a free gathering to thank the first batch of subscribers, and future subscribers. There won’t be any official program, just some food and drink and fellowship of leaders from the Seattle biotech community who are supporting this biotech journalism venture. There will also be a couple door prizes. Sources say a FitBit may be involved. East Coast readers, never fear, I am planning a similar launch party for you next month in Boston.
I have one request. Although the event is free, if you plan to attend, please RSVP here so that I can get an accurate headcount for the food and drink order. That’s it. See you in Seattle on March. 20.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Welcome to a new adventure in biotech journalism.
After a year in the writer’s cave, the Lee Hood book is well on its way. It can now be converted into a nights and weekends project as I come down the stretch with editing. It has been a wonderful reporting challenge putting such a complicated life under the microscope. But I have missed the action of day-to-day journalism. It’s my passion. We’re living in a wonderfully creative time for biotech, and it’s a privilege to write about it. The main question for me has been how to find, or create, the right platform for doing what I love to do.
The answer is here, at the Timmerman Report. After years of writing about startups, I’m doing my own. The idea is simple. For $99, I will give biotech professionals like you a year’s worth of in-depth news, features, and original commentary to help you get ahead. For $25, graduate students and postdocs can get the same information to advance their careers. On the side, I will continue to write a handful of biotech stories a month for Forbes.
That’s it. There’s no magic algorithm, no investors, no need for user-generated content, no maximizing of eyeballs. No advertising or sponsored content will be accepted. The price is low enough at $99 per individual that there’s no need for a group corporate rate. (If more than one person at a company wants to read this publication, then more than one subscription is required.)
The Timmerman Report aspires to offer you a clean, simple reading experience—whether it’s on your smartphone, tablet, or computer at work. Most importantly, this is a business designed to support the kind of journalism that will give you less heat and more light. By offering a high-quality product at a low price, my hope is that the Timmerman Report will become one of your favorite, go-to sites for biotech news and analysis. I will strive to ask hard, constructive questions, and write in an accessible way about complicated subjects. It’s the sort of clear, probing and contextual journalism that never goes out of style.
I hope you’ll join me on this new adventure, this new mountain that I’m itching to climb.
